Notícias

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Hims & Hers Health (NYSE:HIMS) and its peers.

Hims & Hers Health is shifting its core weight-loss business from compounded GLP-1 drug sales to branded versions of the medications.

Check out the companies making headlines yesterday:

Hims & Hers Shares Sink as Visa Targets Credit Card Disputes

Hims faces an estimated $75,000 surcharge and must lower its dispute rate below 1.5%.

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) fell 9.2% in the afternoon session after Bloomberg reported that Visa enrolled the telehealth company in its Acquirer Monitoring Program following a surge in customer credit card disputes in its weight-loss subscription business.

Visa placed Hims & Hers Health into its Acquirer Monitoring Program after a billing dispute spike, adding penalty costs amid an FTC lawsuit and margin contraction.

TDOC's BetterHelp faces a capacity crunch as insurance demand surges, putting therapist recruitment and credentialing at the center.

When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fear their firms will lose out in other business lines such as M&A advisory.

Hims & Hers Health (HIMS) stock is back in focus after the Federal Trade Commission and state regulators filed a civil enforcement action, followed by a consumer class action targeting the company’s telehealth privacy and subscription practices. See our latest analysis for Hims & Hers Health. The latest 1-day share price return of 6.03% and 7-day return of 20.00% put Hims & Hers Health back in sharp focus. However, the 1-year total shareholder return is down 24.21%, while the 3-year total...

Hims & Hers Health (HIMS) was placed on notice by Visa for excessive customer complaints in its weig

Hims & Hers' rally is fueled by branded weight-loss growth, international expansion, AI efficiencies and a broader specialty portfolio.

Hims & Hers Health, Inc. (NYSE:HIMS) shares fell over 2% on Tuesday even after the telehealth company posted second-quarter revenue of $753.2 million, up 38% and above the $699 million analysts expected. The firm raised its full-year revenue outlook. Novo Nordisk A/S (NYSE:NVO) suffered a similar fate a week earlier, with shares dropping about 6% […]

The gap between its revenue multiple and its cash multiple is margin, and the company is spending it on purpose.

This filing notes that shares were withheld automatically to cover tax obligations from quarterly RSU vesting.

Soleil Boughton retains roughly 339,000 shares and additional derivative securities.

This tax-related withholding was tied to quarterly RSU vesting, not discretionary selling.

Tax withholding drove the disposal of 10,201 shares at $28.15 each, reducing this insider's direct holdings by 5%, though they're still up on a net basis given conversions.

This non-discretionary sale was tied to RSU tax withholding; the insider retains 65,734 direct shares and 428,000 derivative securities, per the filing.

The disposition comes as HIMS stock has declined 38% over the past 12 months.

This non-discretionary tax withholding reduced the CTO of Hims' direct holdings, though he retains roughly 194,000 shares and roughly 2 million derivative securities subject to multi-year vesting.

Stock-based compensation vesting triggered mandatory tax withholding, but Dudum retains about 9.7 million shares worth $272 million.

Hims & Hers Health (NYSE:HIMS) is facing a new consumer class action lawsuit alleging misrepresentation of user privacy and unauthorized sharing of sensitive health data. The lawsuit follows a recent FTC civil enforcement action against the company that raised similar concerns about handling of consumer health information. Plaintiffs claim the company misled users about how their health data would be used and shared, potentially affecting customer trust and future regulatory scrutiny. As...

Andrew Dudum told CNBC the agency wanted "more of a headline than a real agreement" after years of cooperative talks

Speaking in an interview with CNBC on Tuesday, Dudum said an AI coach could remind patients to take their medicine, monitor side effects and even connect with healthcare providers.

Investing.com -- Hims & Hers Chief Executive Andrew Dudum defended the telehealth company against a Federal Trade Commission lawsuit concerning its data sharing practices in an interview that aired Tuesday on CNBC's "Squawk Box."

Andrew Dudum explained CNBC that the FTC’s lawsuit is just a misunderstanding of what he’s doing... but maybe the regulator might understand him just fine?

CEO Andrew Dudum marked the company’s fifth listing anniversary by ringing the NYSE opening bell and declaring its “next phase of growth.”

Subscriber growth accelerated as revenue surged 38% and international expansion took off.

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the legendary stocks that return 100 times your money.